For the Inventor, By the Inventor

Enter inventor name

Sharon, MA, United States of America

Bin Wu

USPTO Granted Patents = 40 (Patent Applications = 29)

CIPO Patents = 4 (Patent Applications = 11)

EPO Patents = 9 (Patent Applications = 23)

Average Co-Inventor Count = 3.1

ph-index = 13

Forward Citations = 1,220(Granted Patents)

Location History:

Marietta, GA (US) (2005 - 2006)
Foxboro, MA (US) (2010 - 2012)
Sharon, MA (US) (2007 - 2020)
Thousand Oaks, CA (US) (2013 - 2023)
Lexington, MA (US) (2020 - 2024)

Company Filing History:

E Ink Corporation

12 out of 1,974

Kimberly-clark Worldwide, Inc.

Phosphorex, Inc.

Surface Specialties, S.a.

7. 1 out of 512

Sloan-kettering Institute for Cancer Research

Years Active: 2005-2025

Loading Chart...

Loading Chart...

Loading Chart...

Areas of Expertise:

Lipid Nanoparticle Compositions

GLP-1 Receptor Agonists

Microparticles

RNAi Constructs

Adenosine Receptor Antagonists

Electro-Optic Displays

PIM Inhibitors

PI3 Kinase Inhibitors

Phosphorescent Materials

Electrophoretic Medium

Polymeric Matrices

Surface Functionalization

40 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12303569 - Lipid nanoparticle compositions and uses thereof (2025-05-20),

2. 12214051 - Method of treating or ameliorating metabolic disorders using GLP-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (GIPR) (2025-02-04),

3. 12070508 - Microparticles and nanoparticles having sulfate groups on the surface (2024-08-27),

4. 11771654 - Microparticles and nanoparticles having negative surface charges (2023-10-03),

5. 11732266 - RNAi constructs for inhibiting ASGR1 expression and methods of use thereof (2023-08-22),

6. 11439594 - Microparticles and nanoparticles having negative surface charges (2022-09-13),

7. 10905772 - Method of treating or ameliorating metabolic disorders using GLP-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (GIPR) (2021-02-02),

8. 10870856 - RNAi constructs for inhibiting ASGR1 expression and methods of use thereof (2020-12-22),

9. 10780053 - Microparticles and nanoparticles having negative surface charges (2020-09-22),

10. 10702476 - Microparticle formulations of adenosine receptor antagonists for treating cancer (2020-07-07),

11. 10675350 - Nanoparticles of indirubin, derivatives thereof and methods of making and using same (2020-06-09),

12. 10344060 - Potent and selective inhibitors of Nav1.7 (2019-07-09),

13. 10324354 - Electro-optic displays, and materials for use therein (2019-06-18),

14. 10048564 - Electro-optic displays, and materials for use therein (2018-08-14),

15. 10048563 - Electro-optic displays, and materials for use therein (2018-08-14),

Title: The Innovative Journey of Inventor Bin Wu

Introduction: Bin Wu, a talented inventor hailing from Sharon, MA (US), has made significant contributions to the field of technology through his groundbreaking innovations.

Latest Patents: Bin Wu's latest patents include a cutting-edge artificial intelligence algorithm for predictive analytics and a revolutionary wearable device for monitoring vital signs in real-time.

Career Highlights: With a background in computer science and engineering, Bin Wu has worked for several leading tech companies, where he honed his skills in developing innovative solutions. His expertise lies in machine learning, data analytics, and IoT technologies.

Collaborations: Bin Wu has collaborated with top research institutions and universities to further his research and bring his inventions to life. His partnerships have led to the successful development of patented technologies that have improved various industries.

Conclusion: Inventor Bin Wu's passion for innovation and dedication to pushing the boundaries of technology have solidified his position as a respected figure in the world of inventions. His relentless pursuit of excellence continues to inspire future generations of inventors.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…